Key result
Dihydroxyanthracenedione treatment resulted in 1 complete and 5 partial responses among 27 evaluable patients with extensively pretreated metastatic breast cancer.
Why the study?
Does dihydroxyanthracenedione improve tumor response in patients with extensively pretreated metastatic breast cancer?
Population
31 patients with metastatic breast cancer extensively pretreated with combination chemotherapy, including…
Design
Case_series
Follow-up
more than 26 weeks
Authors
Loading...
May warrant testing in anthracycline-refractory disease; leaves open efficacy confirmation in randomized trials.
Does dihydroxyanthracenedione improve tumor response in patients with extensively pretreated metastatic breast cancer?
Dihydroxyanthracenedione demonstrates significant clinical activity and a lack of cross-resistance in patients with heavily pretreated, doxorubicin-refractory metastatic breast cancer.
Yap et al. (1981) studied metastatic breast cancer (n=31). dihydroxyanthracenedione was evaluated on complete and partial response. Dihydroxyanthracenedione treatment resulted in 1 complete and 5 partial responses among 27 evaluable patients with extensively pretreated metastatic breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: